EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

Breast Cancer Clinical Trial

Official title:

EXActDNA-003 / NSABP B-64: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06401421
• Other study ID #: 2023-05
• Status: Not yet recruiting
• Start date: May 2024
• Est. completion date: April 2030

Study information

• Verified date: May 2024
• Source: Exact Sciences Corporation
• Contact: NSABP Department of Site and Study Management Department of Site
• Phone: 1-800-270-3165
• Email: industry.trials[@]nsabp.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis.

Participants will be followed for up to 5.5 years.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1800
• Est. completion date: April 2030
• Est. primary completion date: April 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The participant or a legally authorized representative must provide study-specific informed consent prior to study entry.

2. The participant must be = 18 years of age.

3. ECOG performance status 0 or 1.

4. Histologically confirmed invasive carcinoma of the breast.

5. Planned neoadjuvant therapy which includes cytotoxic chemotherapy.

6. Tumor size = 2.1 cm in greatest diameter.

7. Unifocal or multifocal cancer documented to be the same histologic clinical subtype.

8. Clinically node positive or if node negative, any one of the following:

1. TNBC or HER2+ subtype

2. HR+/HER2-negative with at least one of the following:

i. High tumor grade (G3) ii. Ki67 index of 20% or higher iii. High genomic risk (Oncotype DX® (ODX) Breast Recurrence Score of > 25, MammaPrint® High, etc.)

9. Willing and able to comply with the study requirements, which includes the collection of a total of 34 cc (2.5 Tablespoons) of blood for each research blood draw.

10. Available residual tissue from diagnostic biopsy from the breast or an involved ipsilateral lymph node for submission to create a bespoke ctDNA assay.

Exclusion Criteria:

1. Definitive clinical or radiologic evidence of metastatic disease.

2. Initiated neoadjuvant therapy for current breast cancer diagnosis.

3. Synchronous diagnosis of another invasive cancer, other than this breast cancer, except for non-melanoma skin cancers.

4. Completed all therapy (including endocrine therapy) <5 years ago for any previous invasive solid organ malignancy (with exception of non-melanoma skin cancers) including prior breast cancer. Individuals with a prior history of noninvasive (in situ) carcinomas may participate if they have received definitive treatment.

5. Completed all therapy for any previous hematologic malignancy < 5 years ago.

6. Multicentric or contralateral invasive breast cancers.

7. Known pregnancy at time of enrollment.

8. Prior solid organ transplant.

9. Prior allogeneic hematopoietic stem cell transplant.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Diagnostic Test:
• ctDNA MRD test
Blood and tissue samples will be collected for the ctDNA MRD test

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Exact Sciences Corporation	NSABP Foundation Inc

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Core biopsy tissue evaluability rate		3 years
Primary	Distant Recurrence Free Interval (dRFI)		6 years
Secondary	Prevalence of tumor mutations and germline variants		6 years
Secondary	Sensitivity/Specificity		6 years
Secondary	Prevalence of test positivity		6 years
Secondary	Pathologic complete response (pCR) status		6 years
Secondary	Recurrence-free interval (RFI)		6 years
Secondary	Invasive breast cancer-free survival (IBCFS)		6 years
Secondary	Event-free survival (EFS)		6 years
Secondary	Overall survival (OS)		6 years
Secondary	Lead Time		6 years